Neuropsychiatric therapeutics biotech Seaport Therapeutics files for a $100 million IPO
May 1, 2026 News
Neuropsychiatric therapeutics Seaport Therapeutics prices upsized IPO at $18, the high end of the range
Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, raised $255 million by offering 14.2 million shares at $18, the high end of the $16 to $18 range. The company offered 2.4 million more shares than anticipated. Existing shareholder General Atlantic had indicated on $50 million worth of shares in the offering （20% of the deal）。 Seaport raised just over 10% more in proceeds than originally planned.
April 27, 2026 News
Neuropsychiatric therapeutics Seaport Therapeutics sets terms for $201 million IPO, pricing this week
Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, announced terms for its IPO on Monday.
The Boston, MA-based company plans to raise $201 million by offering 11.8 million shares at a price range of $16 to $18. General Atlantic intends to purchase $50 million worth of shares in the offering （25% of the deal）。
IPO Overview
Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Seaport Therapeutics is a clinical-stage biotechnology company developing oral therapies for neuropsychiatric disorders, including depression, anxiety, and other central nervous system conditions. The company uses its proprietary Glyph platform, a lymphatic-targeting prodrug technology designed to improve oral bioavailability and reduce first-pass metabolism, to reformulate clinically validated mechanisms into differentiated product candidates. Its lead programs include GlyphAllo in Phase 2b for major depressive disorder and GlyphAgo in Phase 1 for generalized anxiety disorder, with additional preclinical candidates targeting depressive and related CNS disorders.
The Boston, MA-based company was founded in 2024 and plans to list on the Nasdaq under the symbol SPTX. Seaport Therapeutics filed confidentially on November 21, 2025. Goldman Sachs, J.P. Morgan, Leerink Partners, Citi, and Stifel are the joint bookrunners on the deal.
About the Company
We are a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through our differentiated approach, we identify clinically validated mechanisms which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. We apply our proprietary GlyphTM platform to overcome those limitations and invent innovative oral therapies. Our lead product candidate, GlyphAlloTM （SPT-300 or Glyph Allopregnanolone）， is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression that shares symptomatology with MDD, as a rapidly acting antidepressant with anxiolytic and sleep-promoting effects. Our second product candidate, GlyphAgoTM （SPT-320 or Glyph Agomelatine）， is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder, or GAD, in Australia and MDD in Australia and the European Union, or EU. We are also advancing Glyph2BLSDTM （SPT-348 or Glyph 2-bromo-LSD）， a novel, Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in preclinical studies for depressive disorders.